跳至主要内容
临床试验/NCT00333918
NCT00333918已完成3 期

Efficacy and Safety Study of Topical Bromfenac Ophthalmic Solution vs. Placebo for Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery

Bausch & Lomb Incorporated0 个研究点目标入组 522 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
522
主要终点
Reduction of ocular inflammation

研究概览

简要总结

The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment of ocular inflammation and pain in subjects who undergo cataract extraction and intraocular lens implantation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Scheduled for unilateral cataract surgery with no other ophthalmic surgical procedures planned during cataract surgery
  • Agree to return for all required visits
  • Agree to avoid disallowed medications

排除标准

  • Known hypersensitivity to bromfenac and salicylates

研究组 & 干预措施

1-bromfenac ophthalmic solution

Experimental

sterile ophthalmic solution

干预措施: bromfenac ophthalmic solution (Drug)

2-placebo comparator

Placebo Comparator

sterile ophthalmic solution

干预措施: placebo comparator (Drug)

结局指标

主要结局

Reduction of ocular inflammation

次要结局

  • Secondary efficacy outcome for ocular pain will be the proportion of treated subjects that are pain free

研究者

申办方类型
Industry
责任方
Sponsor

相似试验